In our preliminary cohort of patients, the addition of 4-IPP to bone marrow derived MM cells increased or maintained the CD138- population in 5 out of 6 patients, suggesting that similar mechanisms are at play in vivo. This evidence concerns the gene SDC1 and Miyoshi myopathy.